Volume 62, Issue 11 pp. 2018-2020

Brief Report

Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab

Corresponding Author

Michael T. Meister MD

Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany

Correspondence to: Michael T. Meister, Pediatric Hematology and Oncology, Children's Hospital, Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany. E-mail: [email protected]

Search for more papers by this author

Sandra Voss MD,

Sandra Voss MD

Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany

Search for more papers by this author

Dirk Schwabe MD,

Dirk Schwabe MD

Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany

Search for more papers by this author

Michael T. Meister MD,

Corresponding Author

Michael T. Meister MD

Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany

Search for more papers by this author

Sandra Voss MD,

Sandra Voss MD

Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany

Search for more papers by this author

Dirk Schwabe MD,

Dirk Schwabe MD

Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany

Search for more papers by this author

First published: 24 June 2015

https://doi.org/10.1002/pbc.25621

Citations: 17

Conflict of interest: Nothing to declare

Share a link

Email
Wechat
Bluesky

Abstract

Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.

REFERENCES

1 Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood 1996; 87: 423–438.
10.1182/blood.V87.2.423.bloodjournal872423
CAS PubMed Web of Science® Google Scholar
2 Perlman SL, Boder Deceased E, Sedgewick RP, Gatti RA. Ataxia-telangiectasia. Handb Clin Neurol 2012; 103: 307–332.
10.1016/B978-0-444-51892-7.00019-X
PubMed Google Scholar
3 Schieving JH, Vries de M, van Vugt JMG, Weemaes C, van Deuren M, Nicolai J, Wevers RA, Willemsen MA. Alpha-fetoprotein, a fascinating protein and biomarker in neurology. Eur J Paediatr Neurol 2014; 18: 243–248.
10.1016/j.ejpn.2013.09.003
CAS PubMed Web of Science® Google Scholar
4 Sandoval C, Swift M. Hodgkin disease in ataxia-telangiectasia patients with poor outcomes. Med Pediatr Oncol 2003; 40: 162–166.
10.1002/mpo.10251
CAS PubMed Web of Science® Google Scholar
5 Suarez F, Mahlaoui N, Canioni D, Andriamanga C, Dubois d'Enghien C, Brousse N, Jais J, Fischer A, Hermine O, Stoppa-Lyonnet D. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: A report from the French national registry of primary immune deficiencies. J Clin Oncol 2015; 33: 202–208.
10.1200/JCO.2014.56.5101
PubMed Web of Science® Google Scholar
6 Kelly KM, Hodgson D, Appel B, Chen L, Cole PD, Horton T, Keller FG. Children's oncology group's 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer 2013; 60: 972–978.
10.1002/pbc.24423
PubMed Web of Science® Google Scholar
7 Niehues T, Schellong G, Dörffel W, Bucsky P, Mann G, Körholz D, Göbel U. Immunodeficiency and Hodgkin's disease: Treatment and outcome in the DAL HD 78-90 and GPOH HD95 studies. Klin Padiatr 2003; 215: 315–320.
10.1055/s-2003-45498
CAS PubMed Web of Science® Google Scholar
8 Distel L, Neubauer S, Varon R, Holter W, Grabenbauer G. Fatal toxicity following radio- and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. Med Pediatr Oncol 2003; 41: 44–48.
10.1002/mpo.10275
CAS PubMed Web of Science® Google Scholar
9 Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: The GPOH-HD-2002 study. J Clin Oncol 2010; 28: 3680–3686.
10.1200/JCO.2009.26.9381
CAS PubMed Web of Science® Google Scholar
10 Kropshofer G, Wehl G, Klein-Franke A, Högler W, Meister B. B-cell lymphoma in a girl with ataxia teleangiectasia (A-T) treated with rituximab monotherapy. Pediatr Blood Cancer 2006; 46: 528–529.
10.1002/pbc.20548
PubMed Web of Science® Google Scholar
11 Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study. The Lancet Oncol 2013; 14: 1348–1356.
10.1016/S1470-2045(13)70501-1
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume62, Issue11

November 2015

Pages 2018-2020

Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab

Abstract

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab

Abstract

REFERENCES

Citing Literature

References

Related

Information